DYNDyne Therapeutics, Inc.

HealthcareUSD
$26.37

The financials

Dyne Therapeutics, Inc. by the numbers

Dyne Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$182M−$116Mn/a
Net income−$179M−$111Mn/a
Diluted EPS−$1.08−$0.97n/a

Biotechnology

Ranks #43 of 145 by Smart Score

Compare peers
GPCR+0.19%
Structure Therapeutics Inc.
QURE+0.51%
uniQure N.V.
ARQT-2.5%
Arcutis Biotherapeutics, Inc.
BEAM+0.09%
Beam Therapeutics Inc.
IDYA+0.03%
IDEAYA Biosciences, Inc.
ELVN+2.8%
Enliven Therapeutics, Inc.